Zydus Receives Final Approval from USFDA for Triamterene and Hydrochlorothiazide Tablets

Zydus Cadila has received the final approval from the USFDA to market Triamterene and Hydrochlorothiazide Tablets USP in strengths of 37.5 mg/25 mg and 75 mg/50 mg. It is used for the treatment of high blood pressure. This combination drug is used by patients who have developed or are at risk of having low potassium levels on hydrochlorothiazide. It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad. The group now has more than 195 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04. – Medical Buyer Bureau